IL165950A0 - Compositions and method for the diagnosis and treatment of tumor - Google Patents

Compositions and method for the diagnosis and treatment of tumor

Info

Publication number
IL165950A0
IL165950A0 IL16595004A IL16595004A IL165950A0 IL 165950 A0 IL165950 A0 IL 165950A0 IL 16595004 A IL16595004 A IL 16595004A IL 16595004 A IL16595004 A IL 16595004A IL 165950 A0 IL165950 A0 IL 165950A0
Authority
IL
Israel
Prior art keywords
tumor
diagnosis
compositions
treatment
Prior art date
Application number
IL16595004A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL165950A0 publication Critical patent/IL165950A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Testing Resistance To Weather, Investigating Materials By Mechanical Methods (AREA)
IL16595004A 2002-07-09 2004-12-23 Compositions and method for the diagnosis and treatment of tumor IL165950A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39499802P 2002-07-09 2002-07-09
PCT/US2003/021606 WO2004004662A2 (en) 2002-07-09 2003-07-08 Compositions and methods for the diagnosis and treatment of tumor

Publications (1)

Publication Number Publication Date
IL165950A0 true IL165950A0 (en) 2006-01-15

Family

ID=30115799

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16595004A IL165950A0 (en) 2002-07-09 2004-12-23 Compositions and method for the diagnosis and treatment of tumor

Country Status (7)

Country Link
US (2) US20060062727A1 (xx)
EP (1) EP1572091A4 (xx)
JP (1) JP2006500009A (xx)
AU (1) AU2003249014B2 (xx)
CA (1) CA2491488A1 (xx)
IL (1) IL165950A0 (xx)
WO (1) WO2004004662A2 (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP3502133A1 (en) * 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
EP1951757B1 (en) 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
EP2235059B1 (en) 2007-12-26 2015-02-18 Xencor, Inc. Fc variants with altered binding to fcrn
EP2241578B1 (en) * 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
MY163539A (en) 2011-03-29 2017-09-15 Roche Glycart Ag Antibody fc variants
MY183712A (en) 2012-07-13 2021-03-09 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
MX2019001458A (es) 2016-08-02 2019-07-04 Visterra Inc Polipeptidos modificados y usos de los mismos.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0686162T3 (da) * 1993-02-04 2003-09-22 Borean Pharma As Forbedret fremgangsmåde til refoldning af proteiner
IT1318691B1 (it) * 2000-09-12 2003-08-27 Consiglio Nazionale Ricerche Varianti di proteine allergeniche del gruppo 2 di dermatophagoides.
WO2003086307A2 (en) * 2002-04-12 2003-10-23 The Board Of Trustees Of The University Of Arkansas β2-MICROGLOBILIN (β2m) AND ANTI-β2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS

Also Published As

Publication number Publication date
WO2004004662A2 (en) 2004-01-15
AU2003249014B2 (en) 2009-07-02
WO2004004662A3 (en) 2005-08-11
US20060062727A1 (en) 2006-03-23
US20090181014A1 (en) 2009-07-16
CA2491488A1 (en) 2004-01-15
JP2006500009A (ja) 2006-01-05
EP1572091A2 (en) 2005-09-14
EP1572091A4 (en) 2008-03-05
AU2003249014A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
EP1571968A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
EP1589933A4 (en) COMPOSITIONS AND METHODS FOR DIETUMOR DIAGNOSIS AND TREATMENT
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
EP1578996A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EP1553912A4 (en) COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1575571A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1575480A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
EP1578367A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1572116A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1576137A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
IL162201A0 (en) New methods for diagnosis and treatment of tumours
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith